Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced the availability of BRCAvantageTM, a suite of lab-developed genetic tests (LDT) that identify mutations in BRCA1 and BRCA2genes, which are associated with increased risk of inherited breast and ovarian cancers.
The BRCAvantage service for India provides several of the same features as the service in the United States. These include the use of advanced next-generation sequencing technologies by the Quest Diagnostics Nichols Institute in San Juan Capistrano, Calif., United States and access to genetic counseling in India to help patients and clinicians assess whether testing is appropriate. Patients can also access free home-collection services in 25 cities across India.
The BRCAvantage test helps to identify mutations (abnormal changes) in two genes. These genes are called BRCA1 and BRCA2. Changes in the BRCA1 and BRCA2 genes are responsible for increasing the risk of hereditary breast and ovarian cancer and associated cancers in women, and for prostate and breast cancer among men.